Gilead Sciences Inc. (GILD) announced that additional data from its pivotal Phase 3 PURPOSE 2 trial demonstrated a 96% reduction in HIV infections with Lenacapavir compared to the background HIV incidence among a geographically diverse population of cisgender men and gender-diverse individuals.
The new data are being presented during an oral abstract session on October 8 at the 5th HIV Research for Prevention Conference (HIVR4P) in Lima, Peru.
According to the company, Lenacapavir was highly effective at reducing infections among trial participants: 99.9% of participants did not acquire HIV in the lenacapavir group, with 2 incident cases among 2,179 participants. The results demonstrated superiority of twice-yearly lenacapavir over bHIV, with 96% relative risk reduction, compared with 9 incident cases among 1,086 individuals in the Truvada group. Additionally, twice-yearly lenacapavir was 89% more effective than once-daily Truvada.
Gilead said it will begin regulatory filings for Lenacapavir for pre-exposure prophylaxis (PrEP) by the end of 2024. The company also recently announced voluntary licensing partnerships aimed at expanding future access to Lenacapavir in high-incidence, resource-limited countries.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.